Cuéllar-Garduño N

Idioma: Español
Referencias bibliográficas: 21
Paginas: 159-162
Archivo PDF: 159.26 Kb.

FRAGMENTO

De acuerdo con la Organización Mundial de la Salud (OMS), el cáncer es una de las principales causas de mortalidad a nivel mundial, esto ha condicionado que durante las últimas décadas se hayan incrementado de manera importante el número de fármacos desarrollados para este fin, así como el número de pacientes que son sometidos a estos tratamientos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. www.who.int/

2. Zaniboni A, Prabhu S, Audisio RA. Chemotherapy and anaesthetic drugs: too little is known. Lancet Oncol. 2005;6:176-181.

3. Holmes S. Making sense of cancer chomotherapy. Nurs Times. 1996;92:42-43.

4. Kiyomiya K, Matsuo S, Kurebe M. Differences in intracellular sites of action of Adriamycin in neoplastic and normal differentiated cells. Cancer Chemother Pharmacol. 2001;47:51-56.

5. Flórez J, Armijo JA, Mediavilla A. Farmacología Humana. Cap. 61 y 62: Quimioterapia antineoplásica I y II. 4a. edición, Ed. Masson, 2004. pp. 1039-1078.

6. Lefort AT. Perioperative management of the patient with cancer. Chest. 1999;115:165S-171S.

7. Huettermann E, Junker T, Chatzinikolaou KP. The influence of anthracycline therapy on cardiac function Turing anesthesia. Anesth Analg. 2004;98:941-947.

8. Huettemann E, Sakka SG. Anaesthesia and anti-cancer chemotherapeutic drugs. Curr Opin Anaesthesiol. 2005;18:307-314.

9. Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001;39:517-528.

10. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5:489-496.

11. Kvolik S, Glavas-Obrovac L, Sakic L, Margaretic D, Karner I. Anesthetic implications of anticancer chemotherapy. Eur J Anaesthesiol. 2003;20:859-871.

12. Chlebowski RT, Block JB, Cundiff D, et al. Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. Cancer Treat Rep. 1982;66:121-125.

13. Kennedy KA, Hait WN, Lazo JS. Chemical modulation of bleomycin induced toxicity. Int J Radiat Oncol Biol Phys. 1986;12:1367-1370.

14. Ermens AA, Schoester M, Spijkers LJ, et al. Toxicity of methotrexate in rats preexposed to nitrous oxide. Cancer Res. 1989;49:6337-6341.

15. Rosenow S, Kooistra KL, Powis G, et al. Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. Cancer Chemother Pharmacol. 1986;16:35-42.

16. Rudnick S, Stevenson GW, Hall SC, et al. Halothane potentiates the anti- tumor activity of gamma-interferon and mimics calmodulin-blocking agents. Anesthesiology. 1991;74:115-119.

17. Arian MR, Buggy DJ. Anaesthesia for cancer patients. Curr Opin Anaesthesiol. 2007;20:247-253.

18. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2003;63:81-86.

19. Walker IR, Zapf PW, Mackay IR. Cyclophosphamide, cholinesterase and anesthesia. Aust N Z J Med. 1972;2:247-251.

20. Frenia ML, Long KS. Methotrezate and NSAID interactions. Ann Pharmacother. 1992;26:234-237.

21. Gehdoo RP. Anticancer chemotherapy and it’s anaesthetic implications (Current Concepts). Indian J Anaesth. 2009;53:18-29.